View source for 18562601. PHARMACEUTICAL COMPOSITIONS CONTAINING STABLE AMORPHOUS SOLID SOLUTIONS AND DISPERSIONS simplified abstract (THE TEXAS A&M UNIVERSITY SYSTEM)

=PHARMACEUTICAL COMPOSITIONS CONTAINING STABLE AMORPHOUS SOLID SOLUTIONS AND DISPERSIONS=


==Organization Name==

[[:Category:THE TEXAS A&M UNIVERSITY SYSTEM|THE TEXAS A&M UNIVERSITY SYSTEM]]


[[Category:THE TEXAS A&M UNIVERSITY SYSTEM]]

==Inventor(s)==

[[:Category:Ziyaur Rahman of College Station TX (US)|Ziyaur Rahman of College Station TX (US)]][[Category:Ziyaur Rahman of College Station TX (US)]]

[[:Category:Eman M. Mohamed of College Station TX (US)|Eman M. Mohamed of College Station TX (US)]][[Category:Eman M. Mohamed of College Station TX (US)]]

[[:Category:Sathish Dharani of College Station TX (US)|Sathish Dharani of College Station TX (US)]][[Category:Sathish Dharani of College Station TX (US)]]

[[:Category:Tahir Khuroo of College Station TX (US)|Tahir Khuroo of College Station TX (US)]][[Category:Tahir Khuroo of College Station TX (US)]]

[[:Category:Mansoor A. Khan of College Station TX (US)|Mansoor A. Khan of College Station TX (US)]][[Category:Mansoor A. Khan of College Station TX (US)]]

[[:Category:Phillip Michael Cook of Kingsport TN (US)|Phillip Michael Cook of Kingsport TN (US)]][[Category:Phillip Michael Cook of Kingsport TN (US)]]

[[:Category:Rajendran Arunagiri of Hendersonville TN (US)|Rajendran Arunagiri of Hendersonville TN (US)]][[Category:Rajendran Arunagiri of Hendersonville TN (US)]]

==PHARMACEUTICAL COMPOSITIONS CONTAINING STABLE AMORPHOUS SOLID SOLUTIONS AND DISPERSIONS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18562601 titled 'PHARMACEUTICAL COMPOSITIONS CONTAINING STABLE AMORPHOUS SOLID SOLUTIONS AND DISPERSIONS

**Simplified Explanation:**
This patent application describes pharmaceutical compositions containing poorly water-soluble drugs (PSDs) and sucrose acetate isobutyrate (SAIB). These compositions are in the form of amorphous solid solutions or amorphous solid dispersions, where the PSDs are present in the molecular or amorphous state in the SAIB. The compositions improve the dissolution rate, serum concentration, and overall bioavailability of the drugs.

**Key Features and Innovation:**
- Pharmaceutical compositions with PSDs and SAIB
- Amorphous solid solutions or dispersions
- Improved drug dissolution rate and bioavailability
- Stable against crystallization in elevated temperature and humidity conditions

**Potential Applications:**
- Enhanced oral dosage forms for poorly water-soluble drugs
- Improved drug delivery systems for better therapeutic outcomes

**Problems Solved:**
- Low solubility and bioavailability of poorly water-soluble drugs
- Stability issues in varying environmental conditions

**Benefits:**
- Increased drug dissolution rate in water
- Higher serum maximum concentration (Cmax)
- Greater area under the curve (AUC) for improved drug efficacy

**Commercial Applications:**
Potential commercial uses include the development of advanced drug delivery systems for poorly water-soluble drugs, leading to more effective treatments and improved patient outcomes.

**Questions about Pharmaceutical Compositions with PSDs and SAIB:**
1. How do these compositions improve the bioavailability of poorly water-soluble drugs?
2. What are the key advantages of using SAIB in pharmaceutical formulations?

**Frequently Updated Research:**
Ongoing research may focus on optimizing the formulation of these compositions for specific drug compounds and exploring additional applications in the pharmaceutical industry.


==Original Abstract Submitted==

Pharmaceutical compositions comprising poorly water-soluble drugs (PSDs) and sucrose acetate isobutyrate (SAIB). The compositions are amorphous solid solutions or amorphous solid dispersions where the PSDs are present in the molecular or the amorphous state in the SAIB. The PSDs in amorphous form in the amorphous solid solutions can be stable against crystallization on exposure to elevated temperature and humidity conditions. Oral dosage forms containing the compositions are characterized by a higher dissolution rate in water, a higher serum maximum concentration (Cmax), and/or a greater area under the curve (AUG) than an equivalent oral dosage form without the SAIB.



[[Category:A61K47/26]]
[[Category:A61K9/20]]
[[Category:A61K9/48]]
[[Category:A61K31/436]]
[[Category:A61K31/437]]
[[Category:A61K31/496]]
[[Category:A61K31/506]]
[[Category:A61K31/5365]]
[[Category:A61K31/5377]]
[[Category:A61K31/55]]
[[Category:A61K38/13]]
[[Category:CPC_A61K47/26]]